Lupin, the country’s biggest maker of tuberculosis medicines, has bought Baroda-based Rubamin Laboratories (RLL), which will give it an entry into the global contract research and manufacturing services (CRAMS) business. The deal size was not disclosed.
Rubamin manufactures advanced intermediates and specialises in active pharmaceutical ingredients (APIs) used in drug-making. The eight-year-old company has a wide customer base in Europe. It has a turnover of about $10 million.RLL belonged to the Rubamin Group, whose main business is mining and metallurgy in India and Congo in Central Africa. RLL was hived into a separate company last year.
Sathish Khanna, president, API, Lupin Group, said Lupin was strong in cephalosporins (antibiotics) and the TB drug range and Rubamin specialised in areas Lupin did not operate, which made it a perfect acquisition.
Read more in The Business Standard article.
No comments:
Post a Comment